Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer - PubMed

5 hours ago

Everolimus is used in second-line or later treatment for hormone receptor-positive breast cancer, combined with endocrine therapy.
Interstitial lung disease (ILD) is a significant adverse event associated with everolimus, occurring in 16.0% of patients in the BOLERO-2 trial and 23.5% in the Asian subgroup.
The study retrospectively analyzed 115 patients with metastatic breast cancer treated with everolimus plus endocrine therapy from 2013 to 2022.
28.7% of patients developed everolimus-related ILD (e-rILD), with 15.2% experiencing grade ≥3 and two cases being fatal.
Management of e-rILD included dose continuation, interruption, prednisolone, and steroid pulse therapy.
Subsequent treatment rates were similar between patients with and without e-rILD (73.2% vs. 81.8%).
Drug-related ILD in subsequent treatments occurred in 3.7% of patients with prior e-rILD and 3.3% without, showing no significant difference.
The study concluded that e-rILD does not significantly impact the choice of subsequent treatments or the risk of ILD in later therapies.

Hasty Briefsbeta